Raymond James Financial
MTNB icon

Raymond James Financial’s Matinas BioPharma MTNB Stock Holding History

Raymond James Financial’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-320
Closed -$285 – 6059
2025
Q2 		$285 Buy
+320
New +$234 ﹤0.01% 6744

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Raymond James Financial's MTNB Position: Q3 2025 in Review

Raymond James Financial sold out of Matinas BioPharma (MTNB) in Q3 2025, closing a stake of 320 shares — an estimated $285 sold.

Raymond James Financial first reported a position in MTNB in Q2 2025 and held it in 1 quarter. The position peaked at $285 in Q2 2025. 28 funds tracked by Wall St. Rank hold MTNB as of Q3 2025.

  • Raymond James Financial reported no remaining Matinas BioPharma position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 320 Matinas BioPharma shares in Q3 2025, an estimated $285.
  • Raymond James Financial first reported a position in Matinas BioPharma in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Matinas BioPharma position peaked at $285 in Q2 2025.
  • 28 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.